Figure 3: Multipotent capacity of myxoma derived cells. Immunostaining of subcultured myxoma derived phase-bright cells with connexin 43, myocyte enhancer factor 2C (MEF-2C), cardiac troponin T (cTnT), and α-smooth muscle actin (α-SMA). Scale bar = 10 μm.